Tarsus Pharmaceuticals Inc (TARS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tarsus Pharmaceuticals Inc (TARS) has a cash flow conversion efficiency ratio of -0.071x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.65 Million) by net assets ($348.95 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Tarsus Pharmaceuticals Inc net asset quality index to measure how much of total assets are equity-financed.
Tarsus Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Tarsus Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check TARS cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Tarsus Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tarsus Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Immunome Inc
NASDAQ:IMNM
|
-0.076x |
|
Go Digit General Insurance Ltd
NSE:GODIGIT
|
0.188x |
|
Levi Strauss & Co Class A
NYSE:LEVI
|
0.124x |
|
PSK Inc
KQ:319660
|
-0.026x |
|
Hugo Boss AG
XETRA:BOSS
|
0.076x |
|
Thule Group AB
ST:THULE
|
0.007x |
|
Artisan Partners Asset Management Inc
NYSE:APAM
|
0.354x |
|
Grindwell Norton Limited
NSE:GRINDWELL
|
0.090x |
Annual Cash Flow Conversion Efficiency for Tarsus Pharmaceuticals Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Tarsus Pharmaceuticals Inc from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Tarsus Pharmaceuticals Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $343.43 Million | $-12.45 Million | -0.036x | +90.20% |
| 2024-12-31 | $224.53 Million | $-83.03 Million | -0.370x | +38.00% |
| 2023-12-31 | $196.99 Million | $-117.49 Million | -0.596x | -134.66% |
| 2022-12-31 | $192.90 Million | $-49.03 Million | -0.254x | -1230.69% |
| 2021-12-31 | $166.73 Million | $3.75 Million | 0.022x | +117.65% |
| 2020-12-31 | $165.98 Million | $-21.14 Million | -0.127x | -120.82% |
| 2019-12-31 | $-6.00 Million | $-3.67 Million | 0.612x | -29.99% |
| 2018-12-31 | $-1.35 Million | $-1.18 Million | 0.874x | -- |
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as we… Read more